International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary
- PMID: 21926387
- DOI: 10.1513/pats.201107-042ST
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary
Abstract
Introduction: The American Thoracic Society is a cosponsor of a newly published lung adenocarcinoma classification.
Methods: An international multidisciplinary panel of experts was formed. A systematic review was performed and recommendations were graded by strength and quality of the evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach.
Results: The classification addresses both resection specimens and small biopsies/cytology. The terms bronchioloalveolar carcinoma and mixed subtype adenocarcinoma are no longer used. For resection specimens, new concepts are introduced such as adenocarcinoma in situ and minimally invasive adenocarcinoma for small solitary adenocarcinomas with pure lepidic growth and predominant lepidic growth with ≤ 5 mm invasion, respectively. Invasive adenocarcinomas are classified by predominant pattern after using comprehensive histologic subtyping with lepidic, acinar, papillary, and solid patterns; micropapillary is added. In the new aspect of this classification that provides guidance for small biopsies and cytology specimens, non-small cell lung carcinomas (NSCLC), in patients with advanced stage disease, are to be classified into more specific types, such as adenocarcinoma or squamous cell carcinoma, whenever possible, for several reasons: (1) adenocarcinoma or NSCLC not otherwise specified should be tested for EGFR mutations, because the presence of these mutations is predictive of responsiveness to EGFR tyrosine kinase inhibitors, (2) adenocarcinoma histology is a strong predictor for improved outcome with pemetrexed therapy, and (3) squamous histology is a risk factor for life-threatening hemorrhage with bevacizumab therapy. NSCLC- not otherwise specified by light microscopy alone should be studied with immunohistochemistry and/or mucin stains.
Conclusions: This classification is intended to support clinical practice as well as research investigation and clinical trials.
Similar articles
-
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.J Thorac Oncol. 2011 Feb;6(2):244-85. doi: 10.1097/JTO.0b013e318206a221. J Thorac Oncol. 2011. PMID: 21252716 Free PMC article. Review.
-
IASLC/ATS/ERS International Multidisciplinary Classification of Lung Adenocarcinoma: novel concepts and radiologic implications.J Thorac Imaging. 2012 Nov;27(6):340-53. doi: 10.1097/RTI.0b013e3182688d62. J Thorac Imaging. 2012. PMID: 23086014 Review.
-
Diagnosis of lung adenocarcinoma in resected specimens: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification.Arch Pathol Lab Med. 2013 May;137(5):685-705. doi: 10.5858/arpa.2012-0264-RA. Epub 2012 Sep 12. Arch Pathol Lab Med. 2013. PMID: 22913371
-
The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know.Semin Thorac Cardiovasc Surg. 2014 Autumn;26(3):210-22. doi: 10.1053/j.semtcvs.2014.09.002. Epub 2014 Sep 16. Semin Thorac Cardiovasc Surg. 2014. PMID: 25527015 Free PMC article.
-
New pathologic classification of lung cancer: relevance for clinical practice and clinical trials.J Clin Oncol. 2013 Mar 10;31(8):992-1001. doi: 10.1200/JCO.2012.46.9270. Epub 2013 Feb 11. J Clin Oncol. 2013. PMID: 23401443 Review.
Cited by
-
Remarkable Effect of Gefitinib Retreatment in a Lung Cancer Patient With Lepidic Predominat Adenocarcinoma who had Experienced Favorable Results From Initial Treatment With Gefitinib: A Case Report.J Clin Med Res. 2012 Jun;4(3):216-20. doi: 10.4021/jocmr816e. Epub 2012 May 15. J Clin Med Res. 2012. PMID: 22719810 Free PMC article.
-
Genomic and clinicopathological features of lung adenocarcinomas with micropapillary component.Front Oncol. 2022 Nov 15;12:989349. doi: 10.3389/fonc.2022.989349. eCollection 2022. Front Oncol. 2022. PMID: 36457500 Free PMC article.
-
Different clinicopathological features between young and older patients with pulmonary adenocarcinoma and ground-glass opacity.Sci Rep. 2024 Jul 8;14(1):15679. doi: 10.1038/s41598-024-66910-4. Sci Rep. 2024. PMID: 38977890 Free PMC article.
-
Significance of the epidermal growth factor receptor mutation status and differences among molecular subgroups in surgically resected lung microinvasive adenocarcinoma.Oncol Lett. 2018 Dec;16(6):7057-7067. doi: 10.3892/ol.2018.9539. Epub 2018 Oct 2. Oncol Lett. 2018. PMID: 30546439 Free PMC article.
-
Preliminary results of low-dose computed tomography screening for lung cancer in asymptomatic participants.Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022 Feb 28;47(2):244-251. doi: 10.11817/j.issn.1672-7347.2022.210138. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022. PMID: 35545415 Free PMC article. Chinese, English.
Publication types
MeSH terms
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous